Back to Journals » OncoTargets and Therapy » Volume 9

Repression of the miR-93-enhanced sensitivity of bladder carcinoma to chemotherapy involves the regulation of LASS2

Authors Liu J, Wang H, Wang Y, Li Z, Pan Y, Liu Q, Yang M, Wang J

Received 29 September 2015

Accepted for publication 14 January 2016

Published 29 March 2016 Volume 2016:9 Pages 1813—1822


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Dekuang Zhao

Peer reviewer comments 2

Editor who approved publication: Dr Faris Farassati

Jingyu Liu,* Haifeng Wang,* Yan Wang, Zhenkun Li, Yi Pan, Qiying Liu, Mingying Yang, Jiansong Wang

Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Yunnan Institute of Urology, Yunnan Province, People’s Republic of China

*These authors contributed equally to this work

Abstract: The aberrant expression of miRNA has an important function in bladder cancer (BC). Previous studies indicate that LASS2 is involved in the development of sensitivity to chemotherapy in cancer cells. In the present study, the miRNAs related to LASS2 were selected by using miRNA profiling to distinguish chemo-resistant and chemo-sensitive tumor specimens from patients. Higher levels of miR-93 were observed in the cisplatin-resistant BC cell line RT4, compared to the cell line T24. The role of miR-93 in chemo-sensitivity was demonstrated both in cell culture and mouse tumor xenograft models. We found that inhibiting miR-93 promoted cisplatin-induced apoptosis due to the accumulation of DNA damage. A reporter gene assay was performed, and the results showed miR-93 was not a target of the 3' untranslated region of LASS2, but had an altered protein expression level. Inhibitors of miR-93 could also enhance the chemo-sensitivity of tumor cells transfected with si-LASS2, but the effect was very slight. These findings suggest that miR-93 plays an important role in the chemo-sensitivity of BC, and may be involved in regulating the LASS2 gene.

Keywords: miRNA, inhibition, chemo-sensitivity, bladder cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]